Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SALT LAKE CITY, May 05, 2017 -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today that its shares of common stock will be quoted under the symbol “GBSN” beginning today, May 5, 2017. The common stock was previously quoted under the temporary symbol “GBSND” on the OTCQB market as a result of the reverse stock split of its issued and outstanding shares of common stock that became effective on April 10, 2017.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses, and significantly limiting the spread of infectious disease. More information can be found on the Company’s website at www.gbscience.com.
Forward-Looking Statements
This press release may include forward-looking statements which involve risks and uncertainties, and which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Company Contact: Betsy Hartman, Great Basin Scientific 385.215.3372 [email protected]
